欧盟法规
REACH注册ECHA物质ECHA物质C&L通报REACH预注册上下游产品
propylphosphonous acid cyano-propyl-phosphinic acid propyl ester propyl bromide diethyl propylphosphonatemethyl hydrogen propylphosphonate propanephosphonic acid dimethyl ester diethyl propylphosphonate 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide 合成工艺路线路线简述
- 合成目标产物 Propane-1-Phosphonic Acid 主要起始原料 Diethyl 1-Propanephosphonate
- (文献来源)合成步骤主要原料 Diethyl 1-Propanephosphonate
📜Cyano-Propyl-Phosphinic Acid Propyl Ester置于盐酸体系中,化学反应生成 丙基膦酸
参考文献:Petrow Et Al.,Zhurnal Obshchei Khimii,1959,Vol. 29,P. 1827,1830;Engl.Ausg.S.1798,1800
标题:Petrow Et Al.,Zhurnal Obshchei Khimii,1959,Vol. 29,P. 1827,1830;Engl.Ausg.S.1798,1800
专利信息
专利号:WO-2021014395-A1
优先权日:2019-07-24
标题:Process for the synthesis of deuterated capsaicin, capsaicinoids and synthetic capsaicin analogs
发明人:ORUGANTI SRINIVAS; AMRUTAPU SRAVANTH KUMAR; SAMPATH MAGESH; SEN SAIKAT
权利人:DR REDDY’S INST OF LIFE SCIENCES
摘要:The present application provides novel processes for the synthesis of deuterated intermediates of capsaicinoids, particularly II, III, IV and V of capsaicinoids, relating to pharmaceutical applications. The invention also provides novel intermediates of compounds of formula IX, XIV, XV, XVI, XVII, XVIII, XX and XXI utilized in the process of making deuterated capsaicin II, III, IV and V.
专利号:US-2003125243-A1
优先权日:2000-07-20
标题:Synthesis of cyclic peptides
发明人:LIU JUN; DAI XUEDONG; SU ZHUANG
摘要:The cyclic pentapeptide cyclo(-Arg-Gly-Asp-D-Phe-Lys-) is a highly potent and selective inhibitor for the α v β 3 integrin. A related compound, cyclo(-Arg-Gly-Asp-D-Phe-Val-), is a promising anticancer drug candidate; it has been found to inhibit angiogenesis and induce apoptosis in vascular cells. We have developed a synthesis of arginine containing cyclic peptides using the cyclizcation reagent 1-propanephosphonic acid cyclic anhydride (T3P) and the guanidine protecting group, 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pbf). This improved synthesis is environmentally friendly and is generally applicable to the synthesis of other cyclic peptides.
专利号:US-11891375-B2
优先权日:2021-07-26
标 题 :Method for the synthesis of 2,4-dimethylpyrimidin-5-ol, intermediates, and method for the synthesis of Lemborexant using the intermediates
发明人:AKHATOU ABDESLAM; DOBARRO RODRÃ?GUEZ ALICIA
权利人:MOEHS IBERICA SL
摘要:A method is for the synthesis of 2,4-dimethylpyrimidin-5-ol, which can be used as an intermediate compound in the synthesis of Lemborexant. The method includes reacting a nitrophenyl compound with N,N-dimethylformamide diethyl acetal.
专利号:US-8927708-B2
优先权日:2013-03-26
标 题 :Process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine
发明人:LE FLOHIC ALEXANDRE
权利人:SERVIER LAB
摘要:Process for the synthesis of the compound of formula (I): n nwherein R represents a para-methoxybenzyl (PMB) group or the following group:n n nApplication in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.
专利号:US-2024067694-A1
优先权日:2021-01-04
标 题:Synthesis of teduglutide
发明人:GANGA RAMU VASANTHAKUMAR; PATIL NITIN; SUVARNA DEEPA SHANKAR
权利人:BIOCON LTD
摘要:The present invention provides for novel synthetic approach of solid phase synthesis of peptides with C-terminal Aspartic acid by anchoring the side chain carboxylic group of aspartic acid to the solid support to avoid the formation of various impurities and thus resulting in higher yield and ease the purification process. The present invention further provides the usage of free amino acids and reducing agents as antioxidants in the cleavage cocktail to negate the formation of oxidative impurities formed during the global cleavage and isolation of the peptide from solid support.
专利号:US-2003083352-A1
优先权日:2000-07-31
标 题 :Synthesis of imidazole intermediates
发明人:HELAL CHRISTOPHER J
权利人:PFIZER
摘要:The invention provides a method for synthesis of compounds of formula n n n wherein R 1 and R 19 are as defined. Compounds of formula 12 are useful as intermediates for synthesizing compounds having pharmacological activity inhibiting cdk5, cdk2, and GSK-3.